Medications Categories - tgiHealthCareerp

U.S. Food and Drug Administration Approves Opdivo (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma

08/30/2021 Administrat, and, Drug, Food, U.S.

PRINCETON, N.J.–(BUSINESS WIRE) August 20, 2021 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 240 mg every

Medications

Have Vaccines, Will Travel: On the Road With a Covid Entrepreneur

08/17/2021 Have, on, travel, Vaccines, Will

VIRGINIA CITY, Mont. — While many businesses in this southwestern Montana “ghost town” reel in tourists with its mining and

Medications

Pfizer CEO to Public: Just Trust Us on the Covid Booster

08/13/2021 CEO, just, Pfizer, public, to, Tru

Pfizer CEO Albert Bourla was confident in June about the ability of his company’s vaccine to protect against the highly

Medications

FDA Approves Keytruda (pembrolizumab) Plus Lenvima (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma

07/26/2021 (pembrol, Approves, FDA, Keytruda

KENILWORTH & WOODCLIFF, N.J.–(BUSINESS WIRE) July 22, 2021 — Merck (NYSE: MRK), known as MSD outside the United States and

Medications

FDA Approves Rezurock

07/22/2021 Approves, FDA, Rezurock

FDA Approves Rezurock (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD) NEW YORK, NY / ACCESSWIRE /

Medications

FDA Approves Rylaze

07/02/2021 Approves, FDA, Rylaze

FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma DUBLIN, June 30, 2021 /PRNewswire/ — Jazz

Medications

FDA Approves Merck’s Keytruda (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

05/11/2021 Approves, FDA, Keytruda, Merck’s

KENILWORTH, N.J.–(BUSINESS WIRE) May 5, 2021– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced

Medications

FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status

04/18/2021 (nivolumab), Adenocarcinoma, advanced, and, Approves, cancer, chemotherapy, Combination, Esophageal, expression, FDA, for, gastric, gastroesophageal, in, Junction, metastatic, of, Opdivo, or, Patients, PD-L1, regardless, status, with

PRINCETON, N.J.–(BUSINESS WIRE)– April 16, 2021 Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall

Medications

KHN’s ‘What the Health?’: Good and Not-So-Good News on Covid

03/04/2021 and, COVID, Good, health, KHN’s, News, Not-So-Good, on, The, What

Can’t see the audio player? Click here to listen on SoundCloud. There’s good news and bad news on covid-19 this week.

Medications

FDA Approves Libtayo (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-Small Cell Lung Cancer with PD-L1 Expression of ≥50%

02/22/2021 (cemiplimab-rwlc), ≥50%, advanced, Approves, cancer, Cell, expression, FDA, First-line, for, Libtayo, lung, Monotherapy, Non-Small, of, Patients, PD-L1, with

TARRYTOWN, N.Y. and PARIS, Feb. 22, 2021 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration

← Previous